Switch theme
Sign up to access all valuation multiples
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
1975
7.7K+
LTM Revenue $2.5B
LTM EBITDA $452M
$5.9B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Bio-Rad Laboratories has a last 12-month revenue (LTM) of $2.5B and a last 12-month EBITDA of $452M.
In the most recent fiscal year, Bio-Rad Laboratories achieved revenue of $2.6B and an EBITDA of -$2.1B.
Bio-Rad Laboratories expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Bio-Rad Laboratories valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.5B | XXX | $2.6B | XXX | XXX | XXX |
| Gross Profit | $1.4B | XXX | $1.4B | XXX | XXX | XXX |
| Gross Margin | 56% | XXX | 54% | XXX | XXX | XXX |
| EBITDA | $452M | XXX | -$2.1B | XXX | XXX | XXX |
| EBITDA Margin | 18% | XXX | -83% | XXX | XXX | XXX |
| EBIT | $308M | XXX | $269M | XXX | XXX | XXX |
| EBIT Margin | 12% | XXX | 10% | XXX | XXX | XXX |
| Net Profit | $272M | XXX | -$1.8B | XXX | XXX | XXX |
| Net Margin | 11% | XXX | -72% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $714M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Bio-Rad Laboratories's stock price is $228.
Bio-Rad Laboratories has current market cap of $6.2B, and EV of $5.9B.
See Bio-Rad Laboratories trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5.9B | $6.2B | XXX | XXX | XXX | XXX | $9.66 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Bio-Rad Laboratories has market cap of $6.2B and EV of $5.9B.
Bio-Rad Laboratories's trades at 2.3x EV/Revenue multiple, and -2.8x EV/EBITDA.
Equity research analysts estimate Bio-Rad Laboratories's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Bio-Rad Laboratories has a P/E ratio of 22.9x.
See valuation multiples for Bio-Rad Laboratories and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $6.2B | XXX | $6.2B | XXX | XXX | XXX |
| EV (current) | $5.9B | XXX | $5.9B | XXX | XXX | XXX |
| EV/Revenue | 2.3x | XXX | 2.3x | XXX | XXX | XXX |
| EV/EBITDA | 13.1x | XXX | -2.8x | XXX | XXX | XXX |
| EV/EBIT | 19.2x | XXX | 22.0x | XXX | XXX | XXX |
| EV/Gross Profit | 4.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | 22.9x | XXX | -3.4x | XXX | XXX | XXX |
| EV/FCF | 20.4x | XXX | 22.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBio-Rad Laboratories's last 12 month revenue growth is 1%
Bio-Rad Laboratories's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Bio-Rad Laboratories's rule of 40 is -24% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Bio-Rad Laboratories's rule of X is 19% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Bio-Rad Laboratories and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 1% | XXX | 1% | XXX | XXX | XXX |
| EBITDA Margin | 18% | XXX | -83% | XXX | XXX | XXX |
| EBITDA Growth | -4% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -24% | XXX | -83% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 19% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 12% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 43% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Bio-Rad Laboratories acquired XXX companies to date.
Last acquisition by Bio-Rad Laboratories was XXXXXXXX, XXXXX XXXXX XXXXXX . Bio-Rad Laboratories acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Bio-Rad Laboratories founded? | Bio-Rad Laboratories was founded in 1975. |
| Where is Bio-Rad Laboratories headquartered? | Bio-Rad Laboratories is headquartered in United States of America. |
| How many employees does Bio-Rad Laboratories have? | As of today, Bio-Rad Laboratories has 7.7K+ employees. |
| Who is the CEO of Bio-Rad Laboratories? | Bio-Rad Laboratories's CEO is Mr. Norman Schwartz. |
| Is Bio-Rad Laboratories publicy listed? | Yes, Bio-Rad Laboratories is a public company listed on NYS. |
| What is the stock symbol of Bio-Rad Laboratories? | Bio-Rad Laboratories trades under BIO ticker. |
| When did Bio-Rad Laboratories go public? | Bio-Rad Laboratories went public in 1980. |
| Who are competitors of Bio-Rad Laboratories? | Similar companies to Bio-Rad Laboratories include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Bio-Rad Laboratories? | Bio-Rad Laboratories's current market cap is $6.2B |
| What is the current revenue of Bio-Rad Laboratories? | Bio-Rad Laboratories's last 12 months revenue is $2.5B. |
| What is the current revenue growth of Bio-Rad Laboratories? | Bio-Rad Laboratories revenue growth (NTM/LTM) is 1%. |
| What is the current EV/Revenue multiple of Bio-Rad Laboratories? | Current revenue multiple of Bio-Rad Laboratories is 2.3x. |
| Is Bio-Rad Laboratories profitable? | Yes, Bio-Rad Laboratories is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Bio-Rad Laboratories? | Bio-Rad Laboratories's last 12 months EBITDA is $452M. |
| What is Bio-Rad Laboratories's EBITDA margin? | Bio-Rad Laboratories's last 12 months EBITDA margin is 18%. |
| What is the current EV/EBITDA multiple of Bio-Rad Laboratories? | Current EBITDA multiple of Bio-Rad Laboratories is 13.1x. |
| What is the current FCF of Bio-Rad Laboratories? | Bio-Rad Laboratories's last 12 months FCF is $290M. |
| What is Bio-Rad Laboratories's FCF margin? | Bio-Rad Laboratories's last 12 months FCF margin is 11%. |
| What is the current EV/FCF multiple of Bio-Rad Laboratories? | Current FCF multiple of Bio-Rad Laboratories is 20.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
